Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence

American Journal of Psychiatry

Volumn 168, Issue 7, 2011, Pages 675-679

  Fishman, Marc J ^a,b,c   Wu, Li Tzy ^a,b,c   Woody, George E ^a,b,c,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d RADARS Scientific Advisory Board ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CHLORDIAZEPOXIDE; DIAMORPHINE; METHADONE; NALOXONE; NALTREXONE; OPIATE; OXYCODONE; RISPERIDONE; SERTRALINE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; AMBIVALENCE; ANORGASMIA; CASE REPORT; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EVENING DOSAGE; FEMALE; HUMAN; OPIATE ADDICTION; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; SUICIDAL IDEATION; TACHYCARDIA; TREATMENT DURATION; TREMOR;

ADULT; ALCOHOLISM; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; DRUG PRESCRIPTIONS; FEMALE; HUMANS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 79960495146     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.10060879     Document Type: Conference Paper

References (38)

1. Wu LT, Woody GE, Yang C, Blazer DG: Subtypes of nonmedical opioid users: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2010; 112:69-80
2. Wu LT, Woody GE, Yang C, Blazer DG: How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med 2011; 5:28-35
3. Substance Abuse and Mental Health Services Administration: Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, Md, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2009
4. Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW: The "black box" of prescription drug diversion. J Addict Dis 2009; 28:332-347
5. McLellan T, Lewis DC, O'Brien CP, Kleber HD: Drug dependence: a chronic mental illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689-1695
6. Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R: Buprenorphine tapering schedule and illicit opioid use. Addiction 2009; 104:256-265
7. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan T, Vandergrift BV, O'Brien CP: Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 1997; 14:529-534 (Pubitemid 28053042)
8. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:210-218 (Pubitemid 43213883)
9. Hulse GK, Morris N, Arnold-Reed D, Tait RJ: Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 2009; 10:1108-1115
10. Fishman M, Winstanley E, Curran E, Garrett S, Subramaniam G: Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction 2010; 105:1669-1676
11. Comer SD, Collins ED, Fischman MW: Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 2002; 301:266-276 (Pubitemid 34250304)
12. Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88:75-78 (Pubitemid 46400304)
13. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL: Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009; 1:1-5
14. Mammen K, Bell J: The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother 2009; 10:2537-2544
15. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE: Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-580 (Pubitemid 24192243)
16. Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P: Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73-77
17. Kintz P: Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121:65-69
18. National Institute on Drug Abuse: Buprenorphine: An Alternative Treatment for Opioid Dependence (Research Monograph 121). Rockville, Md, National Institute on Drug Abuse, 1992
19. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS: Counseling plus buprenorphine-naloxone maintenance treatment in primary care. N Engl J Med 2006; 355:365-374 (Pubitemid 44127539)
20. Gunderson EW, Fiellin DA: Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs 2008; 22:99-111
21. Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O'Connor PG, Schottenfeld RS, Fiellin DA: Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med 2007; 22:242-256
22. Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA: Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009; 37:426-430
23. Gunderson EW, Wang X-Q, Fiellin DA, Bryan B, Levin FR: Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010; 5:537-540
24. Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, Cunningham CO: Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat 2010; 38:153-159
25. Hasin D, Liu X-H, Nunes E, McCloud S, Samet S, Endicott J: Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry 2002; 59:375-380 (Pubitemid 34275256)
26. Aharonovich E, Liu X, Nunes E, Hasin DS: Suicide attempts in substance abusers: effects of major depression in relation to substance use disorders. Am J Psychiatry 2002; 159:1600-1602 (Pubitemid 35006746)
27. Reynaud M, Petit G, Potard D, Courty P: Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93:1385-1392 (Pubitemid 28430045)
28. Kintz P: A new series of 13 buprenorphine-related deaths. Clin Biochem 2002; 35:513-516
29. McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM: Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict 2010; 19:30-37
30. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH: Effects of methadone on QT-interval dispersion. Pharmacotherapy 2005; 25:1523-1529 (Pubitemid 41566911)
31. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC: QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387-395
32. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC: QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167:2469-2475 (Pubitemid 350254906)
33. Woody GE, Poole S, Subramaniam G, Dugosh K, Bogenschutz M, Abbot P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P: Extended vs short-term buprenorphine-naloxone for treatment of opioid addicted youth: a randomized trial. JAMA 2008; 300:2002-2011
34. Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG: Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010; 106:56-60
35. Stotts AL, Dodrill CL, Kosten TR: Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10:1727-1740
36. Stein MD, Cioe P, Friedmann PD: Buprenorphine retention in primary care. J Gen Intern Med 2005; 20:1038-1041
37. Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS: Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict 2008; 17:116-120 (Pubitemid 351507728)
38. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA: The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005; 79:113-116